Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ABBV stock price vs ZBH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZBH's multiple
Needs ZBH P/E.
Implied fair value · at ABBV's multiple
Needs ABBV P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Bear
$74.44
Base
$92.88
Bull
$117.70
ZIMMER BIOMET HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
ABBV vs PFE
Johnson & Johnson
ABBV vs JNJ
Merck & Co., Inc.
ABBV vs MRK
Eli Lilly and Company
ABBV vs LLY
Amgen Inc.
ABBV vs AMGN
Gilead Sciences, Inc.
ABBV vs GILD
STRYKER CORP
ABBV vs SYK
Medtronic plc
ABBV vs MDT
Orthofix Medical Inc.
ABBV vs OFIX
SMITH & NEPHEW PLC
ABBV vs SNN
CONMED Corp
ABBV vs CNMD
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABBV can sustain its premium valuation through continued margin strength and high ROIC, then hold or accumulate selectively because its operating profile is much stronger than ZBH’s despite the expensive multiples; if you prioritize ZBH-relative and DCF discipline, the data argues for caution given the large implied downside to $58.15.
ABBV trades at a large premium to ZBH on every valuation multiple shown, with P/E at 110.6x versus 24.6x and EV/EBITDA at 25.3x versus 12.0x. The model’s implied price of $58.15 versus the current $261.07 suggests -77.7% downside, while ABBV still sits inside its historical band but well above both ZBH-implied range and DCF range.
Supporting Metrics
